WHO ICTRP trial
Effect of Rosuvastatin Therapy on HDL2 Level andAntiatherosclerotic Reverse…
ChiCTR-IPR-15007184 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-IPR-15007184 |
|---|---|
| Public title | Effect of Rosuvastatin Therapy on HDL2 Level andAntiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD patients with hyperlipidemia |
| Scientific title | Effect of Rosuvastatin Therapy on HDL2 Level andAntiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD patients with hyperlipidemia |
| Primary sponsor | Daping Hospital,Third Military Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | Post-market |
| Countries | China |
| Conditions | Coronary heart disease (CHD).hyperlipidemia |
| Interventions | 2:rosuvastatin |
| Registration date | Oct 10, 2015 |
| Target size | 2:300 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: